NewBiologix Expands with U.S. Subsidiary Launch
NewBiologix, an innovative technology company focused on the production of viral vectors for gene and cell therapy, has recently launched its U.S. subsidiary. This strategic expansion aims to enhance the company’s support and offerings in the large and dynamic biotech market.
Strategic Appointment of David Kelly
As part of this expansion, NewBiologix has named David Kelly as the Business Development Manager for its U.S. operations. Kelly brings over ten years of experience in gene and cell therapy, along with expertise in stem cell manufacturing and commercial development. His role will involve overseeing sales, client support, and exploring licensing opportunities for NewBiologix’s services across the U.S. and Canada.
Experience and Vision
David Kelly expressed his enthusiasm about returning to the gene and cell therapy sector, highlighting NewBiologix's commitment to enhancing production efficiencies in the field. His vision is to lead the company’s business development efforts effectively as demand for innovative therapies rises in the biotechnology sector.
Xcell™ Portfolio: An Advanced Solution
In conjunction with its new U.S. presence, NewBiologix recently unveiled its Xcell™ Portfolio, a comprehensive suite of technologies designed to address quality challenges in rAAV production. The portfolio integrates proprietary HEK293-based cell lines with cutting-edge analytical testing services, facilitating a smoother transition from research to commercialization in the gene therapy space.
Components of the Xcell™ Portfolio
The Xcell Portfolio includes several key products:
- Xcell™ Eng-HEK293 Cell Line: A sophisticated cell line tailored for high-performance rAAV production.
- Xcell™ rAAV Production & Analytics Platform: A pioneering platform that streamlines the production and analytical assessment of rAAV candidates.
- Xcell™ Genomic Analytical Platform: Custom sequencing and bioinformatics solutions aimed at a variety of scientific challenges.
Leadership on Innovation and Collaboration
CEO Igor Fisch emphasized the importance of the U.S. market for NewBiologix, stating that the company's expansion reflects its dedication to delivering Swiss-engineered solutions tailored to meet market needs. Fisch shared his optimism about David Kelly's leadership, noting that his experience is essential for deepening collaboration within the biopharma community in the United States.
Contact Information for Collaborations
Gene and cell therapy companies interested in learning more about NewBiologix's capabilities can reach out to David Kelly for discussions around rAAV production and other related services.
About NewBiologix
NewBiologix is committed to revolutionizing gene and cell therapy with innovative solutions originating from Switzerland. By providing advanced technologies and robust support, NewBiologix is driving efficiency and reliability in gene therapy production, fostering new opportunities in patient health solutions.
Frequently Asked Questions
What is the main focus of NewBiologix?
NewBiologix specializes in developing advanced technologies for the efficient production of viral vectors used in gene and cell therapy.
Who is David Kelly?
David Kelly is the newly appointed Business Development Manager for NewBiologix's U.S. operations, bringing extensive experience in gene and cell therapy.
What is the Xcell™ Portfolio?
The Xcell™ Portfolio is a suite of advanced technologies aimed at improving rAAV production quality and facilitating the development of gene therapies.
How can companies contact NewBiologix?
Companies in the U.S. can reach out to David Kelly to discuss their needs in gene and cell therapy solutions.
What markets is NewBiologix expanding into?
NewBiologix is expanding into the U.S. biotech market to enhance its customer support and service offerings.
